Bulk Pharmaceutical API Sources for sprycel

Bulk Pharmaceutical API Sources for sprycel

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-846-143
Oakwood Products		078952
BioChemPartner		BCPP000263
AbMole Bioscience		1701
BioChemPartner		BCP9000589

Bulk Active Pharmaceutical Ingredient (API) Sources for SPRYCEL

Last updated: February 20, 2026

What are the primary sources of SPRYCEL (dasatinib) API?

SPRYCEL (dasatinib) is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The API sourcing landscape comprises multiple manufacturers, with key players providing bulk dasatinib through different regions and capacities.

Who are the leading API suppliers for dasatinib?

Major APIs for dasatinib originate mainly from generic and branded drug manufacturers. The primary sources include:

• Boehringer Ingelheim (Branded production)
• Sun Pharmaceutical Industries (India)
• Dr. Reddy’s Laboratories (India)
• Cipla (India)
• Zhejiang Horizon Pharmaceutical Co., Ltd. (China)
• Hetero Labs Ltd. (India)
• Sandoz (Novartis) (Branded and generic)

The API manufacturing ecosystem further extends through Contract Manufacturing Organizations (CMOs), which supply dasatinib for various formulations.

Regional API supply dynamics

Region	Key Suppliers	Market share / Capacity	Remarks
India	Sun Pharma, Dr. Reddy's, Hetero Labs, Cipla	60-70% of global supply	Dominates bulk API production; cost-effective manufacturing
China	Zhejiang Horizon Pharmaceutical, others	20-25%	Growing presence; regulatory hurdles persist
Europe/US (Branded)	Boehringer Ingelheim	Small-scale, exclusive	Primarily supplies branded versions, not API at large volume

Quality and regulatory considerations

API suppliers for SPRYCEL must comply with Good Manufacturing Practices (GMP) established by FDA, EMA, and other authorities. Certificates of Analysis (CoA) and Regulatory Filings (ANDA, DMF) are essential for procurement.

• Boehringer Ingelheim provides high-quality APIs aligned with international standards.
• Indian manufacturers such as Sun Pharma and Dr. Reddy’s maintain GMP certifications for export but face scrutiny on regulatory audits in key markets.

API sourcing trends and risks

• Supply chain diversification is a priority due to geopolitical tensions, regulatory barriers, and quality concerns.
• Geographical concentration in India and China introduces risks related to policy shifts, trade tariffs, and quality compliance.
• Capacity expansions have increased, with new plants in India and China entering the market to meet rising demand.

Contract Manufacturing Organizations (CMOs)

CMOs play a pivotal role, supplying additional API volumes and supporting R&D needs.

CMO Name	Region	Capacity / Specialization	Remarks
AbbVie (through CMOs)	Global	API manufacturing, process development	Strategic partnerships enhance supply
Laurus Labs	India	API synthesis, scale-up	Growing market share in API supply
Hetero Labs	India	API synthesis, large-scale manufacturing	Widely supplied for global markets

Price and sourcing considerations

Prices for dasatinib API vary significantly based on source, quality, and batch size:

• Indian API prices approximate $5-8 per gram.
• Chinese API prices are typically $4-7 per gram.
• Branded API from Boehringer Ingelheim can cost upwards of $50-70 per gram.

Manufacturers weigh cost, quality, and regulatory status in procurement decisions, with quality standards being paramount for approved production.

Summary

The global dasatinib API supply chain primarily involves Indian and Chinese manufacturers, with Indian suppliers holding the majority market share for bulk API. Quality compliance and supply chain diversification remain focal points, influenced by geopolitical and regulatory factors. Contract manufacturing play an expanded role in capacity resilience.

---

Key Takeaways

• Indian manufacturers dominate dasatinib API supply, accounting for the majority of global volume.
• Chinese suppliers contribute to cost-effective API but face regulatory and quality scrutiny.
• Major branded API production from Boehringer Ingelheim is limited and designed for specific markets.
• Supply chain diversification is a strategic objective to mitigate geopolitical risks.
• API prices are highly variable and depend on source, quality, and volume.

FAQs

1. Which manufacturers supply dasatinib API for the US market?
   Indian companies such as Sun Pharma, Dr. Reddy’s, and Hetero Labs supply dasatinib API that comply with FDA requirements for the US market.

2. What factors influence API sourcing decisions for SPRYCEL?
   Quality certification, regulatory approval, cost, supply capacity, and lead times are critical in API sourcing decisions.

3. Are there any alternative API sources outside India and China?
   Some European and US-based API manufacturers exist but at smaller scales and higher costs, primarily for branded products.

4. What are the regulatory hurdles facing API suppliers?
   Suppliers must maintain GMP compliance, pass regular inspections, and submit Certificates of Analysis (CoA) and filings such as DMFs for market authorization.

5. How does API price variability impact SPRYCEL’s manufacturing cost?
   Pricing directly influences production costs, especially for generic formulations; price fluctuations can affect margins and market competitiveness.

---

References

[1] U.S. Food and Drug Administration. (2022). Drug Master Files (DMF).
[2] WHO. (2021). Good Manufacturing Practices (GMP) guidelines for active pharmaceutical ingredients.
[3] Indian Pharmaceutical Association. (2022). API manufacturing and supply trends.
[4] Chinese Pharmacopoeia. (2020). Standards for active pharmaceutical ingredients.
[5] Market Research Future. (2022). API market analysis – dasatinib.